The adjustment in price target by a reputable analyst firm like RBC Capital could have a mixed impact on aTyr Pharma's stock. While maintaining an Outperform rating indicates a positive outlook on the company, the reduction in price target might raise concerns among investors about the potential for growth, leading to a neutral short-term impact.